Nucala Approval History
- FDA approved: Yes (First approved November 4th, 2015)
- Brand name: Nucala
- Generic name: mepolizumab
- Dosage form: Injection
- Company: GlaxoSmithKline
- Treatment for: Asthma, Eosinophilic Granulomatosis with Polyangiitis
Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for the add-on maintenance treatment of patients with severe eosinophilic asthma, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Development History and FDA Approval Process for Nucala
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.